▲ Peaking
Business
New Parkinson’s drug approved in the US: What does it do differently?
US FDA approves first-in-class Parkinson's treatment, JUVMO, from AbbVie
Abbvie
5 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Abbvie
This hub groups 5 separate news trends connected to Abbvie, spanning June 20, 2026 through September 28, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 39 article observations and 38 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials
A US House committee has launched an investigation into Merck and AbbVie regarding drug trials conducted in China.
◼ Archived
Business
🔮 fades ✓
Lilly, J&J and AbbVie Hit New Highs
Lilly, Johnson & Johnson and AbbVie stocks reach unprecedented levels as investors shift from tech to healthcare.
◼ Archived
Business
🔮 fades ✓
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie is expanding its immunology portfolio through a nearly $11 billion acquisition of Apogee Therapeutics.
◼ Archived
Business
🔮 fades ✓
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
AbbVie is reportedly nearing an $11 billion acquisition of biotech firm Apogee Therapeutics to secure an experimental eczema treatment.